Identification of anxiety symptoms in patients with chemotherapy-induced nausea and vomiting undergoing moderately-emetogenic chemotherapy
Yap, Kevin Yi-Lwern, Chan, Alexandre, Low, Xiu Hui and Chui, Wai Keung. (2010) Identification of anxiety symptoms in patients with chemotherapy-induced nausea and vomiting undergoing moderately-emetogenic chemotherapy. Supportive Care In Cancer, Vo.18 (Suppl.3). S189-S189. ISSN 0941-4355Full text not available from this repository.
Official URL: http://dx.doi.org/10.1007/s00520-010-0891-0
Objectives: State anxiety is a risk factor for chemotherapy-induced nausea (N) and vomiting (V). However, objective assessments are not routinely performed to assess patients’ anxiety statuses. This study identifies anxiety characteristics that distinguish patients with and without CINV based on the Beck Anxiety Inventory (BAI), an objective assessment tool.
Methods: NV events were collated from 127 cancer patients undergoing moderately-emetogenic chemotherapy (MEC) consisting of intravenous oxaliplatin (130mg/m2 on day 1, every 21 days) and oral capecitabine (2000mg/m2/day, days 1–14) (XELOX). These events were correlated with 21 anxiety characteristics belonging to the subjective, neuro physiological, autonomic and panic domains of the BAI. Principal Components (PCs) analysis, a mathematical projection method used for investigating relationships among multiple correlated variables and explaining causes of variation in datasets, was used for analysis. An 80% cut-off was used to determine the number of PCs retained. Statistical analysis was performed using the Student’s t-test.
Results: Majority of patients were Chinese (90%) and over 50 years old (87%). Approximately half were males (56%). Higher proportions of patients suffered from delayed than acute NV. Females were significantly more anxious than males (BAI scores: 12.1±9.4 versus 6.7±6.5, p=0.001). Over a third of the variation in anxiety experienced by patients with and without NV was explained by subjective characteristics, including ‘being scared’ (40.1–48.5%) and ‘helplessness’ (34.7–41.4%). ‘Nervousness’ was experienced solely by patients who experienced N. In addition, two neuro-physiological symptoms could be used to distinguish between patients who suffered from acute NV (‘dizziness’, 7.9–8.3% variation in non-sufferers) and delayed NV (‘unsteady gait’, 6.8–11.5% variation in sufferers).
Conclusions: Patients with and without chemotherapy-induced NV while on XELOX therapy report different types of anxiety symptoms. These symptoms are useful as potential measures of state anxiety for clinicians to assess a patient’s CINV risk in their daily practice.
|Item Type:||Journal Article|
|Subjects:||B Philosophy. Psychology. Religion > BF Psychology
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||Faculty of Science > WMG (Formerly the Warwick Manufacturing Group)|
|Journal or Publication Title:||Supportive Care In Cancer|
|Number of Pages:||1|
|Access rights to Published version:||Restricted or Subscription Access|
|Version or Related Resource:||This item was originally presented as a poster at the 2010 International MASCC/ISOO Symposium, Vancouver, British Columbia, Canada, Jun 24-26, 2010.|
Actions (login required)